.png)
georgeclerk
- Citing recruitment problems, Pfizer has ended a phase 2 trial of maplirpacept, a candidate targeting CD47 that the drug giant obtained in August 2021 as part of its $2.26B acquisition of Trillium Therapeutics.
- "The trial terminated due to the inability
English (US) ·